• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » PEA: A Natural Anti-Inflammatory for Mania?
Research Update

PEA: A Natural Anti-Inflammatory for Mania?

February 1, 2024
Kate J. Travis, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Kate Travis, MD. Dr. Travis has no financial relationships with companies related to this material.

REVIEW OF: Abedini T et al, Psychiatry Clin Neurosci 2022;76(10):505–511

STUDY TYPE: Randomized, double-blind, placebo-controlled trial

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide found in foods like peanuts and eggs. It has anti-inflammatory, neuroprotective, and analgesic effects. PEA successfully augmented antidepressants in a small, trial (Hashemi et al, J Affect Disord 2018;232:127–133), and the current study explored its potential in bipolar mania.

Researchers conducted a six-week, randomized, double-blind, placebo-controlled study of PEA as an adjunctive treatment for mania. They enrolled 63 adult patients who were admitted for bipolar mania at two hospitals in Iran. All patients were taking combined lithium (0.8–1.1 mEq/L) with risperidone (3 mg), and half additionally received a PEA tablet (600 mg) while the other half got a placebo pill. Manic symptoms were assessed at baseline and weeks one, two, four, and six by the Young Mania Rating Scale (YMRS). The primary outcome was reduction of YMRS scores from baseline to study endpoint between the PEA and placebo groups.

Patients in the PEA and placebo groups started with statistically similar YMRS scores (31.34 and 29.96, respectively), indicating moderate mania. Those randomized to adjunctive PEA had a significant reduction in YMRS scores compared to placebo at four weeks (-22.46 vs -18.00, p=0.018) and six weeks (-29.06 vs -23.22, p=0.002). Both groups had low YMRS scores at the end of the six-week trial, though scores were significantly lower in the PEA group (2.28 vs 6.74, p=0.004). PEA was well tolerated, with no difference in adverse events between the PEA and placebo groups.

CARLAT TAKE

This study adds to a small but growing body of literature suggesting that anti-inflammatory agents like PEA may be effective adjunctive treatments for acute mania, but we’ll need more than a single study before recommending PEA in practice.

General Psychiatry Research Update
KEYWORDS complementary treatments mood disorders
    Kate J. Travis, MD

    Antipsychotic Dosing: Differences Between Bipolar Mania and Schizophrenia

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Bipolar Disorder, TCPR, February 2024
    Six Recent Disappointments in Psychiatric Research
    Lithium, Antidepressants, and Bipolar Disorder
    New Medications for Insomnia
    PEA: A Natural Anti-Inflammatory for Mania?
    Cognitive Training Extends Ketamine’s Benefits
    CME Post-Test, Bipolar Depression, TCPR, February 2024
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.